Home
Transactions

Work Area: Transactions

BlackBerry will re-start monetisation of remaining patents if sale closes this quarter

CEO John Chen says company will use a third party to extract value from 2,000 patents it is keeping

The European Commission’s SEP licensing plans are terrible on every level

Reported DG Grow proposals designed to make FRAND dealmaking in Europe more transparent, predictable and efficient are one-sided and poorly thought-through, so will do much more harm than good

Janssen’s latest move against Amgen highlights shifting pharma patent strategies

J&J subsidiary makes innovative use of IP acquired in $6.5 billion Momenta acquisition

Latest content

Limitation of goods or services for trademark registration in China

Brand owners are advised to weigh up their business needs when deciding whether to file a national application with the CNIPA or for international registration through the Madrid Protocol (designating China).

24 August 2022

Top university IP head voices concerns about new UK foreign investment law

Imperial College tech transfer chief Vjera Magdalenic-Moussavi says the recent legislation puts dealmaking in danger

23 August 2022

Intel’s mega monetisation deal with IPValue may raise eyebrows but makes perfect sense

The chipmaker spawned the term “patent troll” and has been highly critical of NPEs, but negative business headwinds mean that putting its world-class portfolio of IP assets to work is a no brainer

19 August 2022

The five hub-and-spokes models transforming pharma IP commercialisation

Several approaches have emerged under this banner, each offering advantages and disadvantages

15 August 2022

Musk v Twitter is a reminder that brands must be prepared for targeting by passionate fan bases

The unfolding legal dispute between the ubiquitous social media giant and the billionaire with 100 million followers is set to become the legal battle of the year when it hits court in October

13 August 2022

Pfizer and Amgen fight to avoid patent cliff falls in multi-billion dollar buying sprees

With significant revenue drop-offs from existing branded products set to decline steeply in the second half of this decade, major portfolio acquisitions are a priority for both companies

10 August 2022

IPBC Asia all set for Tokyo this autumn

The Asia-Pacific region’s premier event about the business of IP will take place in the Japanese capital from 31 October to 2 November

10 August 2022

Intel transfers 5,000 assets to IPValue in major patent deal

The portfolio covers a wide range of the tech produced by the Silicon Valley giant and will now be monetised by an entity named Tahoe Research Limited

08 August 2022

The contribution patents make to enterprise value

No commonly used valuation methods are much help at putting a number on an entire portfolio unless there is a specific transaction on the horizon. Cipher’s Nigel Swycher and Steve Harris suggest an original methodology to fill this gap

03 August 2022

Sanofi farms out more IP as part of “play to win” strategy

The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months

29 July 2022

Unlock unlimited access to all IAM content